Researchers, policymakers to gather at AIDS Vaccine 2012 conference in Boston

NewsGuard 100/100 Score

"With a completed trial in Thailand that offered evidence a vaccine could be developed to protect people from HIV, emerging science identifying antibodies against HIV, and a current trial testing a novel vaccine combination against the virus potentially producing more information in the next year, this is an exciting time to hold a conference, organizers of AIDS Vaccine 2012 say," the Center for Global Health Policy's "Science Speaks" blog reports. "AIDS Vaccine 2012, which begins this Sunday and runs through Wednesday in Boston, will bring together about 1,000 participants, 120 scientists and scholars, discussion of 440 research studies, and speakers that, along with Massachusetts Governor Deval Patrick and National Institute of Allergy and Infectious Diseases Director Anthony Fauci, will include researchers known for work in HIV treatment as prevention of transmission, pre-exposure antiretroviral treatment as prevention (PrEP -- or pre-exposure prophylaxis), and topical microbicides," the blog notes (Barton, 9/6).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Novel vaccine approach effective against all virus strains